ArticleTherapeutic advances in medical oncology2026
Consolidation thoracic radiotherapy after chemoimmunotherapy provides survival benefit in elderly patients with extensive-stage small-cell lung cancer: a multicenter study.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have demonstrated that thoracic radiotherapy (TRT) following first-line chemoimmunotherapy improves survival in extensive-stage small cell lung cancer (ES-SCLC). However, its efficacy and safety in elderly patients remain unclear. Objectives: To evaluate the efficacy and safety of consolidative TRT in elderly patients with ES-SCLC following first-line chemoimmunotherapy. Design: A multicenter retrospective cohort study. Methods: Elderly (⩾70 years old) ES-SCLC patients from three large-scale cancer centers who received chemoimmunotherapy in the first line were included, they were divided into two groups according to whether they received TRT. The primary outcomes were overall survival (OS) and progression-free survival (PFS). Results: A total of 240 patients who completed four to six of first-line chemoimmunotherapy without progression were included, 83 of whom received consolidative TRT. In the analysis with time zero set at chemoimmunotherapy initiation, TRT was associated with longer median PFS (10.56 vs 8.30 months; hazard ratio (HR), 0.71, Conclusion: In elderly ES-SCLC patients undergoing first-line chemoimmunotherapy, the addition of TRT is associated with a survival benefit and an acceptable safety profile. These results hold significant implications for current clinical practice and may help inform treatment strategies for elderly patients with ES-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.